NTLA vs. SCHD
Compare and contrast key facts about Intellia Therapeutics, Inc. (NTLA) and Schwab US Dividend Equity ETF (SCHD).
SCHD is a passively managed fund by Charles Schwab that tracks the performance of the Dow Jones U.S. Dividend 100 Index. It was launched on Oct 20, 2011.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NTLA or SCHD.
Performance
NTLA vs. SCHD - Performance Comparison
Returns By Period
In the year-to-date period, NTLA achieves a -54.18% return, which is significantly lower than SCHD's 15.93% return.
NTLA
-54.18%
-32.12%
-46.72%
-46.31%
0.99%
N/A
SCHD
15.93%
-0.59%
9.36%
25.99%
12.42%
11.46%
Key characteristics
| NTLA | SCHD | |
|---|---|---|
| Sharpe Ratio | -0.76 | 2.25 |
| Sortino Ratio | -0.98 | 3.25 |
| Omega Ratio | 0.89 | 1.39 |
| Calmar Ratio | -0.52 | 3.05 |
| Martin Ratio | -1.68 | 12.25 |
| Ulcer Index | 28.17% | 2.04% |
| Daily Std Dev | 62.04% | 11.09% |
| Max Drawdown | -92.10% | -33.37% |
| Current Drawdown | -92.10% | -1.82% |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Correlation
The correlation between NTLA and SCHD is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Risk-Adjusted Performance
NTLA vs. SCHD - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Schwab US Dividend Equity ETF (SCHD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NTLA vs. SCHD - Dividend Comparison
NTLA has not paid dividends to shareholders, while SCHD's dividend yield for the trailing twelve months is around 3.41%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NTLA Intellia Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
SCHD Schwab US Dividend Equity ETF | 3.41% | 3.49% | 3.39% | 2.78% | 3.16% | 2.98% | 3.06% | 2.63% | 2.89% | 2.97% | 2.63% | 2.47% |
Drawdowns
NTLA vs. SCHD - Drawdown Comparison
The maximum NTLA drawdown since its inception was -92.10%, which is greater than SCHD's maximum drawdown of -33.37%. Use the drawdown chart below to compare losses from any high point for NTLA and SCHD. For additional features, visit the drawdowns tool.
Volatility
NTLA vs. SCHD - Volatility Comparison
Intellia Therapeutics, Inc. (NTLA) has a higher volatility of 29.13% compared to Schwab US Dividend Equity ETF (SCHD) at 3.55%. This indicates that NTLA's price experiences larger fluctuations and is considered to be riskier than SCHD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.